The rapidity and duration of the response of non-transferrin-bound iron (NTBPI) t o chelation therapy are largely unknown and have important implications for the design of optimal chelation regimens. Methodology was developed t o measure simultaneously NTBPI, deferoxamine (DFO), and its major metabolite. NTBPI was present in all but 2 of 28 thalassaemia major (TM) patients who had received conventional subcutaneous DFO the previous night, suggesting a short duration of NTBPI clearance by DFO. The detailed kinetics of NTBPI were therefore studied in response t o intravenous DFO at 50 mg/kg/27 h for 48 hours and compared in 17 regularly transfused TM and 8 untransfused thalassaemia intermedia (TI) patients t o determine the influence of hypertransfusion and iron overload on NTBPI response. Before DFO infusion, NTBPI was present in all patients and was significantly higher in TI (4.52 f 0.53 pmol/L) than TM (2.92 ? 0.03 pmol/L; P = .03). NTBPI values in TM correlated with transferrin saturation (r = .6, P = .03) but not with serum HE IMPORTANCE OF non-transferrin-bound iron T (NTBPI) in iron overload was first recognized by Hershko and Rachmilewitz' and Hershko et aL2 Despite initial skepticism, subsequent studies confirmed the existence of NTBPI by a variety of method^^.^ as well as demonstrating that NTBPI can generate harmful hydroxy radicals and promote lipid per~xidation.~ NTBPI has not yet become a routine measurement in the treatment of iron overload, partly because of the technical difficulty in its reliable measurement. There also seems to be relatively weak correlations with other markers of iron o~e r l o a d ,~.~ and it is unclear how best to use NTBPI measurement in monitoring chelation treatment. Very little is known about the kinetics of NTBPI, particularly in response to chelation therapy, partly because it has previously been difficult to differentiate NTBPI from low molecular complexes of iron chelators such as ferioxamine (FO). Without knowledge of how rapidly NTBPI responds to chelation treatment and how quickly such a response is reversed on cessation of treatment, it is not clear how to use NTBPI most effectively as a marker of iron overload and chelation efficacy or indeed of how to plan chelation treatment so as to minimize tissue damage from this form of toxic iron.
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Hershko and Rachmilewitz' and Hershko et aL2 Despite initial skepticism, subsequent studies confirmed the existence of NTBPI by a variety of method^^.^ as well as demonstrating that NTBPI can generate harmful hydroxy radicals and promote lipid per~xidation.~ NTBPI has not yet become a routine measurement in the treatment of iron overload, partly because of the technical difficulty in its reliable measurement. There also seems to be relatively weak correlations with other markers of iron o~e r l o a d ,~.~ and it is unclear how best to use NTBPI measurement in monitoring chelation treatment. Very little is known about the kinetics of NTBPI, particularly in response to chelation therapy, partly because it has previously been difficult to differentiate NTBPI from low molecular complexes of iron chelators such as ferioxamine (FO). Without knowledge of how rapidly NTBPI responds to chelation treatment and how quickly such a response is reversed on cessation of treatment, it is not clear how to use NTBPI most effectively as a marker of iron overload and chelation efficacy or indeed of how to plan chelation treatment so as to minimize tissue damage from this form of toxic iron.
We previously described methodology for the direct quantification of NTBPI in patients undergoing chelation therapy with deferoxamine (DFO), using nitrilotriacetic acid (NTA), ultrafiltration, and UV detection with high-performance liquid chromatography (HPLC). 7 We also recently published methodology to measure both DFO and its metabolites in such patients.'." In this study, we therefore sought to examine the kinetics of removal of NTBPI by DFO in iron-overloaded patients. We aimed to establish how recent chelation treatment might influence NTBPI before DFO infusion as well as the response to DFO therapy once started. We also sought to establish the duration of the response of NTBPI to DFO therapy and how this might be influenced by the degree of iron overload or by the degree of erythropoiesis. After preliminary pilot studies, patients with iron overload were admitted to hospital for 48 hours of continuous intravenous DFO at 50 mg/kg/24 h. The rate at which NTBPI was ferritin. Removal of NTBPI by intravenous DFO is in a biphasic manner. The initial rapid rate constant (a) was similar in TI (1.5 hour-') and TM (1.6 hour-'), but the subsequent fi phase was slower (0.04 hour-') in TI when compared with TM (0.4 hour-', P = .002). Detectable NTBPI persisted during the p phase, particularly in TI, despite an excess of plasma DFO also being present (steady state 8 pmol/L). On cessation of DFO infusion, NTBPI reappearance was rapid; the kinetics also being biphasic. The rapid initial rate constant (a = 2.5 hour-') lasted less than 30 minutes and was approximately equal t o the summation of the initial rate constant for removal of DFO (1.8 hour-') and its major metabolite (0.6 hour-'). This was followed by a slower return t o pretreatment levels, usually between 6 and 12 hours, which was faster in TI than in TM. This marked NTBPI lability supports the use of continuous rather than intermittent DFO in high risk patients. 0 1996 by The American Society of Hematology.
removed by DFO and returned after DFO infusion was then compared in regularly chelated patients with thalassaemia major (TM) and relatively untreated patients with thalassaemia intermedia (TI).
MATERIALS AND METHODS

Patient Selection
All thalassaemia patients were attending the thalassaemia clinic at University College Hospital, London. Local ethical committee approval was granted for the studies. TM patients were receiving regular transfusion every 3 to 4 weeks of two to four units of blood to keep the pretransfusion hemoglobin (Hb) above 10 g/dL and were receiving DFO by subcutaneous (SC) infusion as their regular chelation therapy four to seven nights a week. (TI) patients selected for the study were not receiving regular blood transfusion or regular iron chelation therapy but had significant anemia (Table 1) .
Preliminary Study in Outpatients
Serum samples were taken from 11 healthy adults not on any medication as reference controls. Adult TM patients ( 2 1 8 years), attending the outpatient department at University College Hospital and receiving conventional DFO treatment by SC infusion of 30 to 50 mgkg DFO as a 10 to 12 hour infusion five to seven nights a week, were asked when the previous SC DFO infusion had been completed and a serum sample for NTBPI measurement was taken. TM  TM   TM   TM   TM  TM  TM  TM  TM  TM  TM  TM  TM  TM   TM  TM  TM   TI  TI   TI   TI  TI   TI  TI Samples were also taken for serum iron, total iron-binding capacity (TIBC), and femtin estimation. All samples were taken between 9 am and 12 noon. For the purposes of analysis, patients were divided into those who had received DFO the previous night (ie, infusion ending within last 4 hours) and those who had not taken DFO the previous evening (Fig 1) .
Inpatient Study
Adult patients with TM or TI were admitted to hospital for intravenous DFO therapy. No DFO or oral ascorbate supplements were given for 72 hours before hospital admission. Intravenous cannulae were sited in each arm, and DFO was infused continuously for 48 hours, starting by between 9 am and 1 1 am, at a dose of SO or 100 mglkg124 h in 1 L of saline. Heparinized plasma samples were taken for analysis of levels of DFO and its major metabolite and serum samples for NTBPI estimation, at predetermined time points before and after commencing and stopping the intravenous. DFO infusion. Twenty-four-hour urine samples were collected for iron estimation. Serum samples were also taken for measurement of serum iron, TIBC, and ferritin and Hb (Table I) .
Measurement of NTBPI
NTBPI was assayed in the Department of Haematology UCL using an HPLC method previously described,' which allows the determination of NTBPI even for patients currently receiving DFO. A number of modifications were undertaken to refine the original assay. 4-Morpholinoproprane sulphonic acid (MOPS) buffer was replaced by 5 mmol/L sodium phosphate, pH 7.0. An HPLC system free from metal parts that might come into contact with the sample was used, with nonmetallic polyetheretherketone (PEEK) tubing throughout (Waters Bio-System 625, nonmetallic gradient module with 991 Photodiode Array detector; Millipore UK Ltd, Watford, UK). NTBPI was quantitated by the injection of FeCI, standards (atomic absorption grade; Sigma, Poole, UK) made up in 80 mmol/ L NTA. Standards were routinely run at 0 to IO pmoUL, although the absdrbance was linear up to 40 pmoVL. Under these conditions, the 0 pmol/L standard corresponds to 80 mmoVL NTA. The following steps were taken to standardize the assay further and to minimize iron contamination during ultrafiltration steps.
We found that Amicon Centricon 30 microconcentrator units (Amicon Inc, Beverly, MA) were well suited for separation of the low-molecular-weight iron fraction from transferrin bound iron by ultrafiltration. Previous work performed with other ultrafiltration cones showed that 0.1 moVL HCI liberates iron from the filtration membranes, and this procedure is therefore unsuitable as a means of depleting the units of iron. Hence, to minimize iron contamination, the membranes were prewashed by spinning 1 mL of IO mmolR. NTA (1,OOOg for 5 minutes) followed by 1 mL of deionized water.
Disodium and trisodium salts of NTA (Sigma, Poole, UK)
were prepared separately as 800 mmoVL stocks in deionized water and mixed to obtain 800 mmoVL NTA, pH 7.0. This was added to serum (for 20 minutes at room temperature before ultrafiltration) 1 : l O to obtain a final NTA concentration of 80 mmolk. As the concentration of iron in NTA has not been certified by the manufacturer, different batches may have different inherent iron contents. Therefore, a number of methods were investigated to minimize iron Ultrajiltration.
NTA.
For personal use only. on May 30, 2017. by guest www.bloodjournal.org From contamination of NTA, including treatment with chelating resin or apotransferrin. Treatment of the two sodium salts of NTA with chelating resin (Chelex; Bio-Rad, Hemel Hempstead, UK) overnight at 20°C did not significantly reduce contaminating levels of iron, the concentration of iron in Chelex-treated and untreated 80 mmoVL NTA being 0.12 and 0.13 pmol/L respectively. Dialysis of NTA (800 mmoVL) at pH 7 against apotransferrin (10 mg/mL) for 2 hours at 37°C also failed to reduce iron present in NTA significantly, the concentrations of iron present in apotransfemn-treated and untreated 80 mmom NTA being 0.17 and 0.21 pmol/L, respectively. We therefore elected not to remove iron from the NTA but to standardize the iron concentration in each batch of 800 mmol/L NTA at 20 pmol/L (ie, 2 pmoVL final concentration in serum) by measuring the iron content by atomic absorption spectroscopy and making up the difference with exogenous atomic absorption grade FeCI,. The addition of 80 mmoVL NTA to the serum of normal individuals always results in negative NTBPI values (Fig 1) . These values are less than the 0 pmol/L standard (ie, 80 mmoln NTA alone), presumably because some iron is donated from NTA to transfemn. By standardizing the iron concentration in the NTA, a greater consistency between assays for such negative values was obtained.
The precision of this assay has not been published previously. The interassay coefficient of variation for replicate samples analyzed on six separate days at 6 pmoVL iron was 5.7% and at 2 pmol/L iron was 28.7% (n = 6). In healthy volunteers, the interassay coefficient of variation was 16.9% (n = 6). The interassay coefficient of variation for pooled thalassaemia plasma was 38% (n = 6) at 2.1 pmol/L. The intraassay coefficient of variation for replicate samples run on the same day was 2.45% at 6 p m o m iron and 14.6% at 2 pmol/L iron. All sequential NTBPI samples from a given inpatient were analyzed on the same day.
Kinetic analysis was undertaken on individual patients (Table 2 ) and on TM patients as a group (Fig 3) by and subsequent (p) rate constants were then calculated (in hour-') Assay precision.
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Measurement of DFO Levels
DFO, its major metabolite, and FO were assayed on heparinized plasma samples at the Department of Pharmacy, Kings College, London, as previously described.'-" This method allows determination of free DFO and FO as well as the proportion of the major metabolites present in the original sample after reverse-phase HPLC analysis and simultaneous UV-vis and radioactive detection.'0," The major metabolite of DFO has the structure HO2C(CH2).,NOHCO (CHZ)2CONH(CH2)SNOHCO(CHZ)2CONH(CHz)5NOHCOMe and was first described by Keberle.'2 As FO has greater stability than DFO in solution," DFO was stabilized within 30 minutes of sample collection. An internal prestandard (DFO E) was first added to the plasma sample. A known amount of s9Fe and 56Fe was then added as previously described?" The kinetics for DFO and its metabolites were analyzed as previously described using the trapezoid method to calculate area under the curve (AUC) values?
Other Measurements
Serum ferritin measurement was as previously described." Serum iron and total iron binding capacity (TIBC) were quantitated by the PFT-600 method (American Monitor Corporation, Indianapolis, IN).I4 Reference ranges for Fe and TIBC are 7 to 45 and 45 to 74 pmoVL, respectively. This chromogenic method is unreliable for TIBC measurement in hemolyzed samples and with high levels of other plasma pigments such as bili~ubin.'~ This may explain the unusually low TIBC values (and hence high transfemn saturation) obtained in some TI patients ( Table 1) . TIBC was therefore measured independently by a nonchromogenic method using rate reaction immunonephelometry on a Beckman Array (Beckman Instruments UK Ltd) for transferrin determination. Calibration was achieved using an international transferrin standard (reference preparation for proteins in human serum [RPPHS]; Table 1 ).16 Although there is a good correlation between TIBC by chromogenic and immunologic methods (r = .83), the unusually high saturation obtained with some TI patients is not observed using the immunoassay. Furthermore, the levels of "BPI measured are closer to the levels predicted from the immunoassay than from the chromogenic method. Urine iron was determined by atomic absorption spectroscopy at 248.3 nm as previously described" on centrifuged (800g for 5 minutes) and filtered (0.45 pmol/L) samples taken from 24-hour collections.
Statistical Amlysis
All values shown are the means ? SEM unless otherwise stated. Statistical differences between groups were evaluated using students (unpaired) t-test. To test for correlations between two variables, linear-regression analysis was performed and the correlation coefficient (r) calculated.
RESULTS
Preliminary Outpatient Study
Initial investigations were performed on healthy volunteers and outpatients with TM to determine whether NTBPI values were affected by the degree of iron loading or by the timing of recent SC DFO therapy. No NTBPI was present in healthy adult controls (-0.94 t 0.08 ,umol/L, n = 11).
NTBPI was measured in outpatients receiving conventional doses of DFO (30 to 50 mg/kg/24 h SC over 8 to 12 hours) and related to when treatment was last given. NTBPI was present in all patients who finished treatment more than 24 hours before blood sampling (Fig 1) n = 13). For patients treated the previous night with SC DFO, NTBPI was present in all but two patients (Fig 1) (3.48 +-0.56 ,umoVL, n = 28), suggesting that either the DFO infusion had failed to clear the NTBPI or that NTBPI had returned rapidly after stopping treatment. The detailed inpatient studies described below were therefore undertaken to determine the relationship between the kinetics of DFO infusion and NTBPI removal and reappearance.
NTBPI Before DFO Infusion With Inpatient Study
NTBPI was present in all but 1 patient (no. 13) with TI or TM admitted for intravenous DFO infusion and having not received DFO for at least 72 hours. NTBPI values were significantly higher in TI (4.52 +-0.53) than in TM (2.92 2 0.29) ( P = .026) ( Table 2 ). For TM but not TI patients, there was a weak linear correlation between NTBPI and transferrin saturation, whether the TIBC was derived from chromogenic determinations ( I = .61, P = .016) or by immunoassay ( r = .64, P = .008). There was no correlation between pretreatment values of NTBPI (Table 2 ) and serum ferritin, urinary iron excretion on DFO, or serum iron (Table 1) .
Kinetics of Removal of NTBPI by Intravenous DFO Infusion in TM
An example of the relationship between a 48-hour intravenous DFO infusion at 50 mg/kg/24h is shown in Fig 2. Kinetic analysis was undertaken on individual patients (Table 2) and on TM patients as a group (Fig 3, inset) as described in Materials and Methods. After starting the intravenous DFO infusion, NTBPI was cleared rapidly, being absent by a mean of 5 hours (Fig 3) . Kinetic analysis (Fig 3, inset) shows that removal of NTBPI is in a biphasic manner from which the respective rate constant a and p and the TI,, values were calculated (see Materials and Methods). An initial rapid removal of NTBPI is seen ( a ) (k = 1.23, = 0.56 hours)
followed by a slower (p) phase (k = 0.57, = 1.2 hours). Table 2 shows the kinetic data for NTBPI removal for each patient in the study. The mean rate constants and values for a (1.6 +-0.21/h, T,/2 = 0.6 2 0.21 hours) and p phases (0.44 5 0.05/h, TI/* = 1.9 +-0.3 hours) are in broad agreement with values obtained from the combined data in Fig 3. In three patients, a clear p phase was not discernible on the data available (marked absent). Patients with high pretreatment NTBPI values had higher NTBPI values at 4 hours ( I = .51, P = .038), but by 48 hours of DFO infusion, no correlation remained. Nadir values were generally obtained at approximately 8 hours. The subsequent small increase observed at 48 hours may in part reflect diurnal variation in NTBPI, as serum iron is known to peak at approximately 9 am and trough at 9 pm.
Comparison of NTBPl Removal Kinetics in TI and TM
Unlike the TM patients who took DFO SC regularly until 72 hours before the study, it can be seen in Table 1 that the TI patients were not receiving regular DFO therapy. Furthermore, TI patients were not receiving regular blood transfusions, and this is reflected by the lower Hb values. We wished to establish whether these two factors might influence NTBPI and the rate at which this was removed by DFO. Table 2 ). The second phase of NTBPI removal (p rate constant) is significantly slower for TI (0.04 ? 0.01) than TM (0.47 ? 0.09) (P = .002, Table 2 ) and is of longer duration (Fig 4) . This difference is also reflected by the lower NTBPI at 4 hours in TM (0.02 ? 0.18) than in TI (1.49 ? 0.44, P = .001) ( Table 2 ).
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Relationship of P l a s m DFO and NTBPI Removal
The steady-state DFO concentrations were estimated in the patients shown in Table 2 , from the AUC divided by the duration of infusion (48 hours). It can be seen that steadystate DFO values range from 2 to 96 pmoK (mean 18.2 ? 2.09 pmom). It is clear from Table 2 that NTBPI persists in many patients in the presence of excess DFO, suggesting that (some) NTBPI species are only slowly chelated or are relatively resistant to DFO chelation. Consistent with this, there is no correlation between steady-state DFO values and the rate of NTBPI removal or values at 48 hours ( Table 2) .
When DFO was given at twice the infusion rate (100 mg/ kg124 h) using an otherwise identical protocol to four TM patients (two of whom had also been studied at 50 m a g / 24h), there seemed to be no marked effect on the rate of NTBPI removal, as reflected by similar rate constants for the a (1.26 +-0.45) or / 3 (0.07 ? 0.03) phase.
Kinetics of NTBPI Return on Cessation of DFO Infusion in TM
On cessation of DFO infusion, there was a rapid retum of NTBPI with a fast initial component ( NTBPI values by 12 hours (Table 3) . These values are equivalent to doubling times of 0.29 and 27 hours respectively.
We have previously described that DFO elimination approximates to a two-compartment model with a rapid a phase and a slower p phase: and the results in this study for DFO are consistent with these previous findings. The initial rate constant (a) for NTBPI return (2.3 hour-') is approximately equal to the summation of the initial rate constants for removal of DFO (1.8k) and its major metabolite (0.6 hour-') ( Table 3 ). The subsequent rate constant for NTBPI increase (0.03) beginning after 30 minutes to 1 hour is considerably slower than either the slow / 3 phase of DFO elimination or that of the main metabolite of DFO.
Comparison of Kinetics of NTBPI Return in TI with TM
The initial mean rate constant ( a ) for return of NTBPI in TI patients is 3.1 1 ? 0.71 hour-' was faster than with for TM 2.32 t 0.34 hour-', although this does not reach statistical significance. The subsequent rate constant (p) in TI is 0.062 -+ 0.013 hour-', which is significantly faster than with TM (0.03 & 0.007 hour-' ( P = .015) ( Table 3) . These differences are also demonstrated in Fig 5, where the kinetics of NTBPI return are shown as the mean In of NTBPI values for each time point plotted against time in TM and TI patients. These differences in NTBPI returns cannot be explained by differences in DFO elimination between Th4 and TI ( Table 3) .
Effect of vitamin C on NTBPI while receiving DFO. All patients in this study received no vitamin C supplements for 72 hours before hospital admission. Oral vitamin C is often given as a supplement to patients receiving iron chelation with the expectation of increasing iron excretion." It has been unclear whether this practice is safe, however, as it has been claimed that high doses of vitamin C (0.6 to 2 g daily) are associated with cardiac damage.I9 To determine whether there was a significant effect of vitamin C on NTBPI while DFO infusion was in progress, we elected to prescribe vitamin C at current recommended doses (200 mg orally) once steady-state concentrations of NTBPI and DFO had been reached during a continuous intravenous infusion of DFO at 100 mg/kg/24 h. On two occasions within a 24-hour period, the addition of vitamin C (200 mg orally) had no effect on measurable NTBPI levels either immediately or over the subsequent 6 hours (not shown).
DISCUSSION
This study shows for the first time the kinetic response of NTBPI to DFO chelation therapy. It has not been established how rapidly NTBPI is removed by DFO and how previous chelation treatment, iron overload status, or transfusion regimens affect this rate. How quickly NTBPI returns after stopping treatment and what determines the rate of recovery to pretreatment levels was also unclear before this study. The findings we report above provide important clues as to the nature of NTBPI in iron overload as well as how DFO might best be administered to minimize toxic NTBPI species.
The exact chemical nature of NTBPI in human plasma in iron overload has been the subject of considerable debate. Evidence for low-molecular-weight NTBPI species has been produced both in the absence of iron overload20*2' and in iron-overloaded patients.22323 In iron overload, iron-citrate complexes may pred~minate,~~ although other low-molecular-weight species have been described.21 Higher molecular weight forms of NTBPI, bound to plasma proteins, are also likely to exist as the iron content of plasma ultrafiltrates is only 50% to 70% of that measured by the bleomycin assay in whole plasma or Plasma ferritin may contribute to this higher molecular weight and complexes of iron with other plasma proteins such as albumin (Hider, personal communication) may be important.
Because the chemical nature of NTBPI species in thalassaemia is unclear, the clinical relevance of the iron species used to study NTBPI kinetics in animal models remains uncertain. Nevertheless, such studies have shown that lowmolecular-weight femc and ferrous citrate complexes are cleared rapidly in perfused rat liver by an efficient saturable "first pass" process with K , values of 14 to 22 p m~l / L .~~ This process appears to require the reduction of ferric to ferrous iron, although this step is not rate-limiting. The kinetics of higher molecular weight forms of NTBPI are presently unknown.
In this study, the biphasic removal of NTBPI with DFO chelation fits with a two-compartment model. One explanation for this finding is of a rapidly chelatable NTBPI component and a more slowly chelatable component, possibly of higher molecular weight. However, the in vitro removal of iron from NTBPI citrate complexes (possibly the predominant low-molecular-weight species of NTBPI) by DFO is relatively slow in human plasma, with little or no removal by 40 minutes." Furthermore, animal studies show that ironcitrate complexes are cleared rapidly by first pass through the liver.25 Therefore, the initial rate of NTBPI fall may represent its clearance by the liver once infusion of DFO begins to inhibit the formation of new NTBPI species (formed by iron release from the reticuloendothelial system). The slower second phase of fall, particularly in the TI patients, would then be explained by a slower hepatic clearance of other NTBPI species (presumably of higher molecular weight). Poor treatment compliance with DFO, or lack of it in the TI patients, may increase the proportion of slowly chelated, higher molecular weight NTBPI species. Whether differences in iron loading between TI and TM could also modulate the rates of liver NTBPI clearance is unclear as there are contradictory findings between the effect of iron loading in whole isolated rat liver (no effect)26 and the cultured human liver tumor HepG2 cell line (increased uptake).*'
A further model that may explain the kinetics of NTBPI removal is that the rapid phase is primarily dependent on the plasma DFO concentration (ie, plasma chelation of NTBPI) but that the subsequent slower phase represents chelation of intracellular iron leading to less release from within reticuloendothelial cells at later time periods. It is known that DFO enters cells relatively slowly, and the rate of the slow phase of NTBPI removal is compatible with this slower rate. This model could also explain the slower second phase in TI compared with TM because the turnover of iron in the former would be greater than in TM. If this model is correct, then the concentration of NTBPI achieved at the end of phase 1 should be inversely proportional to the plasma DFO concentration. Analysis of the data in Table 2 fails to show such a correlation, suggesting that the initial rate of NTBPI removal is not solely dependent on plasma DFO concentrations.
On cessation of DFO infusion, the initial rates of return of NTBPI appear to be largely determined by the rate of clearance of DFO and its major iron chelating metabolite. It is likely that this is a causal relationship, the levels of NTBPI at any time point during the fast phase primarily reflecting plasma DFO concentrations. We have previously shown that DFO elimination corresponds to a two-compartment model with an initial rapid elimination and a slower second phase.' Unlike the initial a phase of NTBPI reaccumulation, the slower second fl phase reaccumulation to pretreatment levels is significantly slower than the rate of DFO elimination (Table 3). This suggests that the second phase of NTBPI reaccumulation is largely independent of DFO kinetics. During this second phase, NTBPI levels are likely to reflect the balance between the rate of formation with release of intracellular iron into the NTBPI compartment and the rate of clearance of NTBPI by the tissues, predominantly hepatocytes. We For personal use only. on May 30, 2017. by guest www.bloodjournal.org From hypothesize that this slower phase of accumulation may correspond to the formation of higher molecular weight NTBPI species that are in equilibrium with lower molecular weight forms.
The difference in reappearance of NTBPI in TI and TM is of interest. The TM patients have significantly higher ferritin values and are regularly transfused and chelated unlike TI patients (Table 1) . Because TI patients are not hypertransfused, the degree of ineffective erythropoiesis and hemolysis is greater, as is the plasma iron turnover.28 If transferrin is already saturated, then NTBPI from these sources will be formed at a greater rate in TI patients than TM. The finding that NTBPI reaccumulates faster in TI than TM (Fig 5 , Table  3 ) suggests that the formation of NTBPI from red cell breakdown is a relatively important contributor to NTBPI turnover and that absolute levels of iron overload less important. The higher pretreatment levels of NTBPI (Table 1 ) therefore may also reflect increased rates of NTBPI formation from red cell breakdown. The levels obtained presumably reflect an equilibrium between formation and clearance in NTBPI, which judging by the time taken to reach pretreatment values ( Figs 3 and 4) , occurs within a few hours of stopping DFO. However, the nature of the NTBPI species may change with time "off treatment" with the gradual accumulation of higher molecular weight forms. This would explain the slower response of the second phase of NTBPI clearance in TI than TM.
This study has implications for the design of chelation strategies. The broad aims of chelation therapy in iron overload are twofold: first, to promote negative iron balance and second, to reduce the harmful effects of iron while or until iron overload is removed. Although intermittent high dosage treatment with DFO may be effective at promoting negative iron balance, this study shows that on cessation of DFO, intravenous NTBPI returns rapidly. Even at higher doses of 100 mgkg, which are above standard recommended doses for prolonged use if DFO toxicity is to be avoided,'? the rate of NTBPI reappearance is rapid, reaching pretreatment levels with 6 hours of cessation of DFO. Thus, for patients who have serious complications such as cardiac dysfunction, this study suggests that it will be more beneficial to give continuous rather than intermittent chelation therapy. This is supported by experimental evidence that NTBPI species are rapidly taken up by myocytes causing lipid peroxidation.24
This study also suggests that the patients with TI may benefit from regular chelation therapy even when the serum ferritin is less than 1,000 pg/L (Table l), if damage from NTBPI is to be minimized. On the other hand, previous studies have suggested that thalassaemia patients with low ferritin values may be at risk from DFO To minimize NTBPI-mediated damage, relatively frequent daily treatment with low doses of DFO (10 to 20 mgkg SC) may be a more logical approach to TI treatment than intermittent administration of doses used to treat TM (40 to 50 mgkg). Unfortunately, although continuous low-dose DFO treatment is logical in TI, problems with compliance may make this impractical in many patients. However, with emerging new oral chelators3' or new preparations of DFO," the design of treatment regimens to minimize the duration of tissue exposure to NTBPI may become increasingly realistic.
